Navigation Links
YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387
Date:11/18/2010

emonstrates the tolerability and durability of response our drug has produced so far," said Dr. Nick Glover, President and COO of YM BioSciences. "We anticipate this trial will be fully enrolled in the first calendar quarter of 2011 and that interim data from the fully-enrolled Phase II portion of the study will be available in mid-2011. We also look forward to the presentation of detailed results from the first 60 patients treated in the Phase I and early Phase II portion of this trial at the American Society of Hematology conference in early December 2010."

Furthermore, subject to regulatory approval, the trial will be expanded from 120 patients to 140 patients to include a 20-patient cohort to be dosed twice-daily at 150mg per dose. "Since we have seen encouraging efficacy signals at the 150 mg and 300 mg once daily dosing levels, it is clearly worthwhile to explore this additional dosing schedule," added Dr. Glover.

In addition to the Stanford Cancer Center, the Company anticipates patients will shortly be enrolled at the Royal Melbourne Hospital (Melbourne, Australia) under Principal Investigator Andrew Roberts, MD; at Princess Margaret Hospital (Toronto, Canada) under Principal Investigator Vikas Gupta, MD; and at the Jewish General Hospital (Montreal, Canada) under Principal Investigator Shireen Sirhan, MD. It is likely that additional clinical centers will join the program in the coming months.  The Phase I/II trial was initiated in November 2009 at Mayo Clinic (Rochester, Minnesota) under Principal Investigator Animesh Pardanani, MD with Ayalew Tefferi, MD as Chair.

"Early data for CYT387 has shown it is capable of reducing spleen size and controlling the constitutional symptoms of myelofibrosis and, importantly, may also provide the additional benefit of improving anemia in these patients. As there are no approved treatments in the United States for this disease, we welcome the opportunity to participate in the clinical deve
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Ardea Biosciences to Present at Two Upcoming Investor Conferences
2. YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results
3. YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS
4. Regado Biosciences Awarded Three Grants from the Federal Government to Advance Research of Lead Programs
5. Sangamo BioSciences Awarded Grants for the Development of Four ZFP Therapeutic® Programs
6. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
7. X-BODY BioSciences Awarded Grant for Therapeutic Discovery Project Targeting Metastatic Tumor Stem Cells
8. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
9. Regado Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference in New York City
10. GeneLink BioSciences, Inc. Ranked 62nd Fastest Growing Company in North America on Deloittes 2010 Technology Fast 500™
11. Sangamo BioSciences Announces Third Quarter 2010 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... -Submission initiates 90-day review period-, SOUTH SAN ... EXEL ) today announced that the company has,submitted ... GlaxoSmithKline,(GSK). As announced in August 2007, GSK requested ... reaches proof-of-concept as defined under the,product development and ...
... Sept. 13 Cadence Pharmaceuticals,Inc. (Nasdaq: ... in-licensing,developing and commercializing proprietary product candidates principally,for ... that Malvina Laudicina has,joined Cadence,s management team ... She will lead the regulatory and quality ...
... CAMBRIDGE, Mass., Sept. 13 Millennium,Pharmaceuticals, Inc. (Nasdaq: ... the Merrill Lynch Global Pharmaceutical, Biotech and Medtech ... by visiting the Investors section,of the Company,s website, ... ) The presentation will include an overview ...
Cached Biology Technology:Exelixis Submits XL880 Diligence Report to GlaxoSmithKline 2Cadence Pharmaceuticals Names Malvina Laudicina Vice President of Regulatory Affairs and Quality Assurance 2Cadence Pharmaceuticals Names Malvina Laudicina Vice President of Regulatory Affairs and Quality Assurance 3Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference to Webcast Millennium Presentation 2
(Date:12/3/2014)... Ariz. , Dec. 2, 2014 As ... hand readers, Inception Technologies is pleased to announce the ... easier for customers to collect the workforce data that ... problems that have been left by existing readers. Many ... user interface, connectivity and modern technology. Older models force ...
(Date:11/21/2014)... Nov. 19, 2014  Earlier this year Donald ... College, and one of the most prolific inventors in ... are transmitted from Smartphones to third party agencies. Spector ... has one of the earliest known patents in this ... in the military, child care, elder care and hospital ...
(Date:11/21/2014)... 20, 2014 C-Labs LLC, a leading provider ... Things (IoT), today announced the appointment of John ... Previously a strategic advisor to the firm, Mr. Traynor ... Traynor is based out of the C-Labs office in ... Chris Muench , Chief Executive Officer. ...
Breaking Biology News(10 mins):Inception Technologies to Release New Biometric Reader 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... a relatively short-term hearing deprivation during childhood may lead to ... The research, published by Cell Press in the March 11 ... like the visual cortex, development of the auditory cortex is ... just the right time. It is well established ...
... sequence exploration on nine BACs of giant panda with ... new genes and repeats were predicted, which greatly fills ... addition, the nine sequences assembled based on traditional phrap ... novo assembly accuracy of the whole genome shotgun sequencing ...
... -- A study of extinction patterns of 25 large mammal ... new areas, and interconnecting them will be necessary for many ... team of researchers from the United States and India, appears ... journal, Proceedings of the Royal Society B . ...
Cached Biology News:Research reveals that temporary hearing deprivation can lead to 'lazy ear' 2Sequencing, annotation and comparative analysis of nine BACs of giant panda (Ailuropoda melanoleuca) 2Large mammals need protected areas, forest cover in India 2
Wheat Germ Agglutinin (WGA) PS SPA Imaging Bead, 2 g. Category: Leadseeker Beads....
... cells (BTI-TN-5B1-4) derived from Trichoplusia ni ... to be capable of expressing significantly ... compared to other insect cells. High ... doubling time as adherent cultures- Quick adaptation ...
Sf9 cells derived from Spodoptera frugiperda ovarian cells (Sf21 cells) are commonly used to isolate and propagate recombinant AcMNPV viral stocks and to produce recombinant proteins....
... Insect Cell Medium is optimized for serum-free ... Cells. In this protein-free medium, Sf9 cultures ... 107 cells/ml with viabilities above 95%. This ... where color from X-gluc staining of pBACgus ...
Biology Products: